Texas 2019 - 86th Regular

Texas House Bill HB2594

Caption

Relating to disposal of controlled substance prescription drugs by hospice service providers.

Impact

This bill significantly impacts state laws regarding the management of controlled substances within the context of hospice care. By formalizing procedures for the disposal of prescription drugs post-death, the bill addresses a critical gap in current regulations that could lead to potential drug abuse if unused medications are not properly disposed of. The law emphasizes a coordinated approach involving healthcare providers, focusing on maintaining safety and health standards in managing sensitive prescriptions.

Summary

House Bill 2594 aims to regulate the disposal of controlled substance prescription drugs by hospice service providers in Texas. This legislation introduces a structured protocol for the safe and responsible disposal of these drugs, which is important in preventing misuse and promoting patient safety. The bill mandates that hospice service providers create written policies about drug disposal that must be communicated to patients and their families. Additionally, healthcare professionals employed by these agencies are required to undergo training on proper disposal methods, ensuring they are equipped to handle sensitive situations appropriately.

Sentiment

The sentiment around HB 2594 appears to be largely positive, especially among healthcare providers and advocates for patient safety, who view it as a necessary measure to prevent drug abuse and safeguard vulnerable populations. By clearly outlining roles and responsibilities, the bill is expected to enhance accountability and trust within hospice services. However, some concerns may arise regarding the logistics and implementation of these disposal protocols, potentially leading to challenges in compliance among providers.

Contention

While the legislation is generally well-received, it does spark discussion regarding the balance between regulation and the operational capabilities of hospice providers. Some stakeholders might argue that imposing strict disposal guidelines could burden small agencies that may lack the resources to implement extensive training and documentation practices. Hence, the debates surrounding HB 2594 reflect a tension between ensuring patient safety and the practical realities of hospice service delivery.

Companion Bills

No companion bills found.

Previously Filed As

TX HB1373

Relating to a pilot program for the safe disposal of controlled substance prescription drugs.

TX SB2173

Relating to a pilot program for the safe disposal of prescription drugs, including controlled substance prescription drugs.

TX HB2767

Relating to the sharing of controlled substance prescription monitoring information between the Texas State Board of Pharmacy and the Health and Human Services Commission for the state Medicaid program.

TX HB2967

Relating to the prescription of a controlled substance for certain patients and continued treatment of those patients.

TX HB343

Relating to the prescriptive authority of certain psychologists; authorizing a fee.

TX SB426

Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.

TX HB1190

Relating to the prescribing and ordering of Schedule II controlled substances by certain advanced practice registered nurses and physician assistants.

TX HB2079

Relating to the authority of pharmacists to order and furnish certain prescription drugs.

TX HB1293

Relating to the reimbursement of prescription drugs under Medicaid and the child health plan program.

TX HB5230

Relating to health benefit plan coverage of prescription drugs for serious mental illnesses and opioid and substance use disorders.

Similar Bills

NJ A3342

Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven day supply, except in certain circumstances.

NJ A3630

Codifies certain regulatory provisions regarding controlled dangerous substances and prescription monitoring.

NJ A2260

Codifies certain regulatory provisions regarding controlled dangerous substances and prescription monitoring.

NJ A2191

Increases amount allowed in initial prescription for opioid drugs in cases of acute pain.

IL HB3472

OPIOID PATIENTS RIGHT TO KNOW

NJ S1327

Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.

NJ A2811

Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.

CT HB07052

An Act Preventing Prescription Opioid Diversion And Abuse.